XML 62 R27.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment Information
 12 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment Information
We manage our operations through two geographic regions. Each operating segment has responsibility for its commercial activities. Within each of these operating segments, we offer a diversified product portfolio, including vaccines, parasiticides, anti-infectives, medicated feed additives, animal health diagnostics and other pharmaceuticals, for both livestock and companion animal customers.
Operating Segments
Our operating segments are the U.S. and International. Our chief operating decision maker uses the revenue and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation.
Other Costs and Business Activities
Certain costs are not allocated to our operating segment results, such as costs associated with the following:
•
Other business activities, includes our CSS contract manufacturing results, our human health business, and expenses associated with our dedicated veterinary medicine research and development organization, research alliances, U.S. regulatory affairs and other operations focused on the development of our products. Other R&D-related costs associated with non-U.S. market and regulatory activities are generally included in the international commercial segment.
•
Corporate, includes platform functions such as business technology, facilities, legal, finance, human resources, business development, and communications, among others. These costs also include compensation costs and other miscellaneous operating expenses not charged to our operating segments, as well as interest income and expense.
•
Certain transactions and events such as (i) Purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and property, plant and equipment; (ii) Acquisition-related activities, where we incur costs associated with acquiring and integrating newly acquired businesses, such as transaction costs and integration costs; and (iii) Certain significant items, which comprise substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis, such as certain costs related to becoming an independent public company, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives that are not associated with an acquisition, certain asset impairment charges, certain legal and commercial settlements and the impact of divestiture-related gains and losses.
•
Other unallocated includes (i) certain overhead expenses associated with our global manufacturing operations not charged to our operating segments; (ii) certain costs associated with business technology and finance that specifically support our global manufacturing operations; (iii) certain supply chain and global logistics costs; and (iv) procurement costs.
Segment Assets
We manage our assets on a total company basis, not by operating segment. Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $11.5 billion and $10.8 billion at December 31, 2019 and 2018, respectively.
Selected Statement of Income Information                                 
 
 
Earnings
 
Depreciation and Amortization(a)
 
 
Year Ended December 31,
 
Year Ended December 31,
(MILLIONS OF DOLLARS)
 
2019

 
2018

 
2017

 
2019

 
2018

 
2017

U.S.
 
 
 
 
 
 
 
 
 
 
 
 
Revenue
 
$
3,203

 
$
2,877

 
$
2,620

 
 
 
 
 
 
Cost of Sales
 
655

 
606

 
565

 
 
 
 
 
 
Gross Profit
 
2,548

 
2,271

 
2,055

 
 
 
 
 
 
    Gross Margin
 
79.6
%
 
78.9
%
 
78.4
%
 
 
 
 
 
 
Operating Expenses
 
543

 
456

 
421

 
 
 
 
 
 
Other (income)/deductions
 
—

 
—

 
(3
)
 
 
 
 
 
 
U.S. Earnings
 
2,005

 
1,815

 
1,637

 
$
44

 
$
34

 
$
29

 
 
 
 
 
 
 
 
 
 
 
 
 
International
 
 
 
 
 
 
 
 
 
 
 
 
Revenue(b)
 
2,972

 
2,890

 
2,643

 
 
 
 
 
 
Cost of Sales
 
925

 
929

 
889

 
 
 
 
 
 
Gross Profit
 
2,047

 
1,961

 
1,754

 
 
 
 
 
 
    Gross Margin
 
68.9
%
 
67.9
%
 
66.4
%
 
 
 
 
 
 
Operating Expenses
 
560

 
559

 
515

 
 
 
 
 
 
Other (income)/deductions
 
—

 
3

 
(1
)
 
 
 
 
 
 
International Earnings
 
1,487

 
1,399

 
1,240

 
53

 
48

 
44

 
 
 
 
 
 
 
 
 
 
 
 
 
Total operating segments
 
3,492

 
3,214

 
2,877

 
97

 
82

 
73

 
 
 
 
 
 
 
 
 
 
 
 
 
Other business activities
 
(348
)
 
(337
)
 
(313
)
 
24

 
23

 
23

Reconciling Items:
 
 
 
 
 
 
 
 
 
 
 
 
Corporate
 
(707
)
 
(666
)
 
(625
)
 
69

 
59

 
52

Purchase accounting adjustments
 
(234
)
 
(162
)
 
(88
)
 
219

 
143

 
88

Acquisition-related costs
 
(43
)
 
(63
)
 
(10
)
 
—

 
—

 
—

Certain significant items(c)
 
(67
)
 
43

 
(25
)
 
—

 
—

 
—

Other unallocated
 
(292
)
 
(339
)
 
(291
)
 
3

 
1

 
6

Total Earnings(d)
 
$
1,801

 
$
1,690

 
$
1,525

 
$
412

 
$
308

 
$
242


(a) 
Certain production facilities are shared. Depreciation and amortization is allocated to the reportable operating segments based on estimates of where the benefits of the related assets are realized.
(b) 
Revenue denominated in euros was $742 million in 2019, $745 million in 2018, and $660 million in 2017.
(c) 
For 2019, certain significant items primarily includes: (i) a change in estimate related to inventory costing of $69 million, (ii) CEO transition-related costs of $10 million, (iii) consulting fees, product transfer costs, employee termination costs and exit costs related to cost-reduction and productivity initiatives of $7 million, and (iv) income of $20 million resulting from a payment received pursuant to an agreement related to the 2016 sale of certain U.S. manufacturing sites.
For 2018, certain significant items primarily includes: (i) a net gain of $42 million related to the divestiture of certain agribusiness products within our International segment, (ii) a net gain of $18 million related to the relocation of a manufacturing site in China, (iii) charges related to our operational efficiency initiative and supply network strategy initiative of $9 million; and (iv) employee termination costs in Europe of $7 million.
For 2017, certain significant items primarily includes: (i) charges related to our operational efficiency initiative and supply network strategy initiative of $20 million; (ii) Zoetis stand-up costs of $3 million; (iii) employee termination costs in Europe of $4 million, (iv) income related to a commercial settlement in Mexico recorded in 2014 and 2016 of $5 million; and (iv) charges of $3 million associated with changes to our operating model.     
(d) 
Defined as income before provision for taxes on income.
B. Geographic Information
Property, plant and equipment, less accumulated depreciation, by geographic region follow:
 
 
As of December 31,
(MILLIONS OF DOLLARS)
 
2019

 
2018

U.S.
 
$
1,342

 
$
1,188

International
 
598

 
470

Property, plant and equipment, less accumulated depreciation
 
$
1,940

 
$
1,658